Protara’s cell therapy shows treatment durability in mid-stage NMIBC study
Protara Therapeutics’ solid tumour-focused cell therapy, TARA-002, has demonstrated its potential to elicit a durable response in patients with non-muscle …
Post
-
-
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma?
On 30 May, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, AstraZeneca will release the …
-
MSD’s sac-TMT meets primary endpoints in Phase III endometrial cancer trial
MSD’s TROP2-directed antibody-drug conjugate (ADC), sac-TMT, has shown benefit in both overall survival (OS) and progression-free survival (PFS) in a …
-
Chronic hepatitis B and multimorbidity
Each May, during Hepatitis Awareness Month, attention turns to the millions of people worldwide living with viral hepatitis, many of …
-
ECO 2026: targeting organs, not just weight, defines next wave of obesity therapy
The European Congress on Obesity (ECO) 2026 has historically focused primarily on weight reduction. However, this year, a shift in …
-
Ipsen reports sustained duration of effect in Phase II corabotase trial
Ipsen has announced Phase II corabotase data in glabellar lines, reporting sustained duration of effect and consistently high patient satisfaction. The first clinical results …
-
The Ovarian Cancer Opportunity: Overcoming Complexity in Global Studies
Each year in the US, more than 21,000 women will receive a new diagnosis of ovarian cancer according to the …
-
Regeneron’s trial fails to reach statistical significance for primary endpoint
Regeneron Pharmaceuticals has reported that its Phase III trial assessing fianlimab (a LAG-3 inhibitor) and cemiplimab (a PD-1 inhibitor) for …
-
Participant enrolment and retention key to clinical trial derisking
As the complexity of clinical trials continues to grow, enhancing patient centricity, improving site and contract research organisation (CRO) collaboration …
-
How to tackle regulatory pathways and obstacles for clinical trials in UK and Ireland
The upcoming Outsourcing in Clinical Trials UK & Ireland 2026 conference, taking place on 9–10 June 2026 in London, UK, …
-
REGENXBIO to push for accelerated approval of DMD gene therapy
REGENXBIO is set to apply for US accelerated approval of its Duchenne muscular dystrophy (DMD) gene therapy after it showed …
-
Nonprofits join forces to debut marketplace for shelved CGTs
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have teamed up to launch an …
-
Tempus broadens collaboration with BMS for clinical trials
Tempus AI has expanded its strategic partnership with Bristol Myers Squibb (BMS) to optimise clinical trial designs across oncology and …
-
Biopharma industry endorses Pazdur for FDA commissioner role
With the leadership role of the US Food and Drug Administration (FDA) vacant following Marty Makary’s resignation earlier this week, …
-
Biogen forges on with Alzheimer’s therapy development despite Phase II miss
Biogen is firing up a registrational programme for its tau-focused Alzheimer’s disease therapy, diranersen, despite the drug missing its primary …
